Please provide your email address to receive an email when new articles are posted on . Incidences of hospitalizations and surgeries were lowest with the vedolizumab-adalimumab sequence in UC and CD.

In this article, Dr Kamdar provides her insights on first-line oral therapy for severely active UC. The landscape for effective, accessible treatments for patients with moderately to severely active ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Please provide your email address to receive an email when new articles are posted on . Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

The clinical management of ulcerative colitis (UC) involves first treating the acute symptoms to induce remission, and then successfully maintaining it. Oral 5-aminosalicylic acids are safe and useful ...

Noninfectious gastroenteritis and colitis are both conditions that affect your digestive tract. While they may lead to similar symptoms, they can have different causes, risk factors, and treatments.